Editas Medicine

Valuation Analysis

About the Company

Editas Medicine en bref

Editas Medicine (EDIT) is currently trading at 2,24 € with a market capitalization of 344 M €. The 52-week range spans from 1,44 € to 3,95 €; the current price is 43.2% below the yearly high. Year-over-year revenue growth stands at -39.2%.

💰 Dividende

Editas Medicine currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

8 analystes évaluent Editas Medicine (EDIT) au consensus : Acheter. L'objectif de cours moyen est de 5,21 €, soit un potentiel de +132.56% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 0,87 € à 13,04 €.

Editas Medicine : la thèse d'investissement en détail

Editas Medicine (EDIT) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Buy with an average price target implying roughly 132.56% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue is contracting at -39.2% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. The debt-to-equity ratio of 392.4% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

À surveiller

• The analyst consensus price target implies 132.56% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to above-average price swings, elevated short interest (14.49%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Editas Medicine?

Compare top-rated brokers — low fees, trusted providers, fully regulated.